New Cedars-Sinai Cancer Center to Include Varian TrueBeam Technology

Cedars-Sinai Cancer Center pic
Cedars-Sinai Cancer Center

Integrated Oncology Network (ION) CEO and founder Jeffrey Goffman leads a Corona del Mar, California-based company that partners with hospitals and physicians in need of financial, management, and strategic assistance. Under the direction of Jeffrey Goffman, ION recently collaborated with the nonprofit hospital Cedars-Sinai to establish a new oncology treatment center in Beverly Hills. In addition to the usual high standard of care offered by Cedars-Sinai, the center will feature Varian TrueBeam linear accelerator technology.

Designed for high-precision treatments, the TrueBeam system brings leading-edge cancer care to patients and advances the fight against cancer. The fully integrated system offers image-guided radiotherapy and radiosurgery, allowing oncologists to treat cancer throughout the body while delivering accurate dose rates. TrueBeam also enhances safety and reduces operation times through an automated workflow that utilizes intuitive visual cues and streamlined imaging.

TrueBeam supports currently accepted advanced treatment forms such as Stereotactic Body Radiation Therapy. Additionally, a history of reliable technology updates help the TrueBeam system maintain its edge in the field of cancer treatment and gives oncologists the peace of mind that the system will be available and effective in the future.


Cancer Survivors Top 15 Million

Oncology Network, LLC pic
Oncology Network, LLC

An entrepreneur with experience leading several companies, Jeffrey Goffman cofounded Integrated Oncology Network, LLC, in 2009. The company provides management advice to oncologists, cancer centers, and hospitals nationwide. Jeffrey Goffman also previously founded OnCURE Medical Corp., a provider of outpatient radiation oncology treatment.

Recent data reveal that more than 15.5 million Americans are cancer survivors.
In addition to the current figures, projections reveal that cancer survivors could top 20 million as soon as 2026, according a recent study in the CA: A Cancer Journal for Clinicians. The study was conducted as a collaborative effort between the National Cancer Institute and the American Cancer Society.

Almost half of the survivors counted in the study are over the age of 70, and more than half of all survivors were diagnosed with cancer within the past decade.

For the purposes of the study, those who are defined as cancer survivors are individuals who either have a history of the disease or are still in treatment but considered cancer-free.

Understanding Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy pic
Duchenne Muscular Dystrophy

A philanthropist and CEO in the healthcare management sector, Jeffrey Goffman serves as chairman of the Board of Directors with CureDuchenne. In his leadership role, Jeffrey Goffman helps the nonprofit organization in its efforts to find life-saving treatments for Duchenne muscular dystrophy.

Muscular dystrophy represents not a single disease, rather it functions as a category encompassing several genetic conditions with progressive symptoms related to muscle atrophy. Some muscular dystrophies begin in adulthood, while others begin in childhood. Duchenne muscular dystrophy is a childhood disease that almost always affects boys.

Symptoms of Duchenne muscular dystrophy can start appearing in infancy and often get worse with time. Muscle weakness, a hallmark of the disease, usually begins in the lower extremities. Eventually, children with the condition lose their ability to walk and may develop breathing as well as cardiovascular problems by early adulthood. Moreover, Duchenne muscular dystrophy may cause intellectual disabilities.

Though there is no cure for the disease, researchers are working on gene therapies, some of which are in early human clinical trials.

About Covenant Health Outpatient Radiation Treatment Center

The co-founder of Integrated Oncology Network, LLC (ION), Jeffrey Goffman was named to the Barney School of Business Hall of Fame in 2014 for his work in national radiation oncology management and cancer center development. Jeffrey Goffman continues to impact the field of oncology by creating partnerships with companies such as Covenant Health.

In September of 2015, ION, subsidiary SightLine Health, LLC, and Covenant Health announced its plans to open Covenant Health Outpatient Radiation Treatment Center in Lubbock, Texas. The facility, supported by the Joe Arrington Cancer Research and Treatment Center, will enhance Covenant Health oncology services by making it more accessible in the community. Health care professionals will have use of modern technologies, like image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT). The latter delivers external beam radiation therapy with precision. IGRT increases IMRT’s effectiveness by sending high doses of radiation directly to treatment areas. This reduces radiation exposure to surrounding tissues.

To learn more about ION’s partnerships, visit

Duchenne Muscular Dystrophy – Severe Muscle Degeneration Disease

Integrated Oncology Network CEO and cofounder Jeffrey Goffman serves as the board chair of CureDuchenne, a nonprofit organization with headquarters in Newport Beach, California. Jeffrey Goffman and his fellow board members help lead the organization in offering support to individuals with Duchenne muscular dystrophy (DMD) and spearheading research efforts for a cure. A devastating muscle disease, DMD affects nearly 20,000 young boys across the United States and over 300,000 worldwide.

DMD is the most common and severe genetic disorder within the muscular dystrophy family. Defects in the genes responsible for producing a vital muscle protein cause the disease, and affected children usually receive the diagnosis before age 5. By the age of 12, patients lose enough leg muscle to become wheelchair bound, and most do not live past their mid-20s. Although it primarily affects boys, a small number of girls may also receive the diagnosis.

Defective genes prevent the body from forming the dystrophin protein, which leads to the progressive degeneration of muscles in nearly every part of the body and eventually compromises heart and lung health. Additional health complications include brittle bones, predisposal to pneumonia and heart failure, and the possible decline of cognitive functions. Patients can also develop fibrosis in the connective tissue between shortened muscle fibers.

CureDuchenne’s research strategies focus on providing support for new treatments to reduce DMD’s severity, drug repositioning, and protein replacement therapies. Since its establishment, the organization has advanced seven projects into human clinical trials and leveraged over $100 million from pharmaceutical companies and government agencies to fund cure research.

For additional information about DMD and the CureDuchenne organization, visit